Revision Medialization Thyroplasty for Glottic Insufficiency Amid Rapid Weight Loss on Semaglutide.

LaryngoscopeJul 13, 2026 (epub)
Case ReportOtolaryngology (ENT)

Katherine Xu, Rachel Weitzman, Michelle Yu et al.

✦ AI-curated · Sources linked

Case in brief

A 74-year-old woman developed new voice deterioration nine years after successful bilateral medialization thyroplasty. The change coincided with a 25-pound weight loss while she was taking semaglutide. Evaluation showed marked vocal fold atrophy and glottic insufficiency. Revision thyroplasty was performed to address the voice changes, with successful restoration of functional voice quality.

What made this case unusual

The report describes glottic insufficiency with marked vocal fold atrophy arising alongside substantial weight loss during semaglutide use, years after initially successful medialization thyroplasty.

Diagnostic / clinical pearl

New voice deterioration after medialization thyroplasty warrants evaluation for vocal fold atrophy and glottic insufficiency, particularly when it coincides with substantial weight loss.

Source

PubMed · PMID 42439301

Published in Laryngoscope. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Otolaryngology (ENT)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.